Certis Oncology Solutions has introduced a groundbreaking innovation: the CertisOI Assistant™, an AI-powered chatbot aimed at significantly enhancing the efficiency of preclinical oncology research. Leveraging the capabilities of artificial intelligence, machine learning (AI/ML), and OpenAI’s ChatGPT language model, the CertisOI Assistant is designed to provide cancer researchers with swift and comprehensive insights into cancer models and drug responses. This advanced tool is set to optimize early drug development decisions, driving greater precision and effectiveness in cancer treatments. The introduction of such technology marks a pivotal moment in the field of oncology, promising to streamline research processes and expedite the journey from preclinical studies to clinical applications.
Innovative AI and Data Integration
At the core of the CertisOI Assistant is its ability to function as a natural language intermediary, effectively bridging the gap between researchers and vast reams of genomic and drug sensitivity data. This data is derived from an array of cancer research models, encompassing Certis’ patient-derived xenograft (PDX) models and public cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE). Moreover, it incorporates the proprietary CertisAI Predictive Oncology Intelligence™ platform, which stands as the first validated AI/ML platform that predicts therapeutic efficacy by pinpointing complex gene expression signatures connected with drug response. This intelligent integration ensures that researchers have access to a unified, comprehensive source of information that facilitates more informed decision-making in preclinical research.
Not only does the CertisOI Assistant provide streamlined access to this wealth of information, but it also offers powerful data visualization capabilities. Users can easily convert query results into visual formats like charts and graphs, which significantly simplifies the interpretation and presentation of data. Additionally, detailed data summaries can be downloaded for sharing, which enhances collaboration among research teams. According to Peter Ellman, President and CEO of Certis Oncology, this tool accelerates scientific investigation by empowering researchers to analyze and interpret complex data efficiently. This capability is crucial for the development of personalized cancer treatments, as it allows for a more nuanced understanding of how different cancer therapies may perform on individual patients.
Certis Oncology’s Commitment to Precision
Certis Oncology Solutions, a trailblazer in life science technology, has been committed to precision oncology since its inception in 2016. Their leading product, Oncology Intelligence®, delivers predictive therapeutic response data from advanced cancer models, aiding researchers and clinicians in evaluating drug efficacy. Certis aims to bridge the gap between preclinical studies and clinical trials with their AI/ML platform and clinically relevant tumor models, providing concrete evidence of drug effectiveness for personalized cancer treatment decisions.
Based in Sorrento Valley, San Diego, Certis’ state-of-the-art laboratory is certified by CLIA, AAALAC, and OLAW, ensuring top-tier quality and reliability. By collaborating with physician-scientists and industry researchers, Certis enhances access to precision oncology tools. The launch of the CertisOI Assistant signifies a breakthrough in cancer research technology. This AI-powered tool offers speed, accuracy, and comprehensive insights, potentially accelerating the discovery of new treatments and improving patient outcomes globally.
In summary, Certis’ introduction of the CertisOI Assistant marks a milestone by integrating AI and machine learning. This tool streamlines genomic and drug sensitivity data access, fostering better collaboration and revolutionizing the development and personalization of cancer treatments.
